1. Zhao Z, Fu T, Gao J, et al. Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors. J Med Genet. 2020;13:13.
2. Blueprint Medicines. Blueprint Medicines announces FDA approval of GAVRETO™ (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer [media release]. 4 Sept 2020
https://www.blueprintmedicines.com
.
3. US Food and Drug Administration. GAVRETO™ (pralsetinib) capsules, for oral use: US prescribing information. 2020.
https://www.blueprintmedicines.com/uspi/GAVRETO.pdf
. Accessed 18 Sept 2020.
4. Blueprint Medicines, CStone Pharmaceuticals. Blueprint Medicines and CStone Pharmaceuticals announce exclusive collaboration and license agreement to develop and commercialize avapritinib, BLU-554 and BLU-667 in greater China [media release]. 4 June 2018
https://www.blueprintmedicines.com
.
5. Blueprint Medicines. Blueprint Medicines announces global collaboration with Roche to develop and commercialize pralsetinib for patients with RET-altered cancers [media release]. 13 July 2020
https://www.blueprintmedicines.com
.